Outcomes of Liver Transplant Recipients With Acute-on-Chronic Liver Failure Based on EASL-CLIF Consortium Definition: A Single-center Study
Recommended Citation
Agbim U, Sharma A, Maliakkal B, Karri S, Yazawa M, Goldkamp W, Podila PSB, Vanatta JM, Gonzalez H, Molnar MZ, Nair SP, Eason JD, and Satapathy SK. Outcomes of Liver Transplant Recipients With Acute-on-Chronic Liver Failure Based on EASL-CLIF Consortium Definition: A Single-center Study. Transplant Direct 2020; 6(4):e544.
Document Type
Article
Publication Date
4-1-2020
Publication Title
Transplant Direct
Abstract
The impact of acute-on-chronic liver failure (ACLF) defined by European Association for the Study of the Liver-Chronic Liver Failure in liver transplant (LT) recipients has not been well characterized. The aim of the study was to assess early posttransplant morbidity and survival of ACLF patients.
Methods: Eight hundred twenty-five consecutive LT patients (04/2006-03/2013) were included in a retrospective analysis. Of the 690 evaluable patients, 589 had no ACLF, and the remaining 101 were grouped into ACLF Grades 1-3 (ACLF Grade 1: 50 [49.5%], ACLF Grade 2: 32 [31.7%], and ACLF Grade 3: 19 [18.8%]).
Results: LT recipients transplanted in the context of ACLF had significantly increased serum creatinine (2.27 +/- 1.16 versus 0.98 +/- 0.32; P < 0.0001), and inferior 1-year graft (90% versus 78%; P < 0.0001) and patient survival (92% versus 82%; P = 0.0004) by Kaplan-Meier survival analysis; graft and patient survival correlated negatively with increasing severity of ACLF. One-year graft and patient survival were lower in those with high ACLF (Grade 2 and 3) irrespective of Model for End-Stage Liver Disease compared with other groups. The ACLF group had longer intensive care unit stays (10.6 +/- 19.5 versus 4.2 +/- 9; P < 0.0001), hospital stays (20.9 +/- 25.9 versus 11.7 +/- 11.4; P < 0.0001), and increased surgical re-exploration (26.7 % versus 14.6%, P = 0.002).
Conclusions: Patients with ACLF undergoing LT have significantly higher resource utilization, inferior graft survival and patient survival, and renal dysfunction at 1 year. The combination of ACLF and Model for End-Stage Liver Disease can be considered when determining the suitability for potential transplantation.
PubMed ID
32309630
Volume
6
Issue
4
First Page
544
Last Page
544
